+

WO2006033012A3 - Method of screening for modulators of hepatitis c virus infection - Google Patents

Method of screening for modulators of hepatitis c virus infection Download PDF

Info

Publication number
WO2006033012A3
WO2006033012A3 PCT/IB2005/003070 IB2005003070W WO2006033012A3 WO 2006033012 A3 WO2006033012 A3 WO 2006033012A3 IB 2005003070 W IB2005003070 W IB 2005003070W WO 2006033012 A3 WO2006033012 A3 WO 2006033012A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
virus infection
modulators
screening
agent
Prior art date
Application number
PCT/IB2005/003070
Other languages
French (fr)
Other versions
WO2006033012A2 (en
Inventor
Romuald Gaston Corbau
Derek John Falconer
Helen Bostock Lavender
Manoussos Perros
Original Assignee
Pfizer Ltd
Pfizer
Romuald Gaston Corbau
Derek John Falconer
Helen Bostock Lavender
Manoussos Perros
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0421360A external-priority patent/GB0421360D0/en
Application filed by Pfizer Ltd, Pfizer, Romuald Gaston Corbau, Derek John Falconer, Helen Bostock Lavender, Manoussos Perros filed Critical Pfizer Ltd
Publication of WO2006033012A2 publication Critical patent/WO2006033012A2/en
Publication of WO2006033012A3 publication Critical patent/WO2006033012A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to an assay method and compounds suitable for use in the treatment of hepatitis C virus infection. In particular, the assay method is suitable for determining whether an agent is capable of modulating Hepatitis C Virus (HCV) infection, the method comprising: (a) contacting the agent with: (i) a first cell line expressing El and E2 proteins on the cell surface; and (ii) a permissive second cell line; and (b) determining whether the agent inhibits fusion between the first and second cell lines, wherein the El and E2 proteins are full length.
PCT/IB2005/003070 2004-09-24 2005-09-19 Method of screening for modulators of hepatitis c virus infection WO2006033012A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0421360.9 2004-09-24
GB0421360A GB0421360D0 (en) 2004-09-24 2004-09-24 Method
US62237704P 2004-10-26 2004-10-26
US60/622,377 2004-10-26

Publications (2)

Publication Number Publication Date
WO2006033012A2 WO2006033012A2 (en) 2006-03-30
WO2006033012A3 true WO2006033012A3 (en) 2006-08-24

Family

ID=36090386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/003070 WO2006033012A2 (en) 2004-09-24 2005-09-19 Method of screening for modulators of hepatitis c virus infection

Country Status (1)

Country Link
WO (1) WO2006033012A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030872A1 (en) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Materials and methods for the treatment of hepatitis c
JP6110846B2 (en) * 2011-05-27 2017-04-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tripeptides with deuterium introduced as hepatitis C virus inhibitors
CN105330730A (en) * 2014-07-29 2016-02-17 中国科学院上海巴斯德研究所 Preparation and application of hepatitis C virus recombinant protein
CN114062070A (en) * 2021-09-27 2022-02-18 苏州德运康瑞生物科技有限公司 Kit for preparing circulating tumor cell quality control product and preparation method of circulating tumor cell quality control product

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160936A1 (en) * 1999-09-29 2002-10-31 Howard J. Worman Hcv e2 protein binding agents for treatment of hepatitis c virus infection
EP1267167A1 (en) * 2001-06-15 2002-12-18 Pfizer Limited Method for identifying HCV entry factors
US20030129746A1 (en) * 1998-03-27 2003-07-10 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
US6635257B1 (en) * 1998-06-24 2003-10-21 Innogentics N.V. Particles of HCV envelope proteins: use for vaccination
US20040115619A1 (en) * 2000-12-01 2004-06-17 Darren Schofield Monoclonal antibodies specific for the e2 glycoprotein of hepatitic c virus and their use in the diagnosis, treatment , and prevention of hepatitis c

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129746A1 (en) * 1998-03-27 2003-07-10 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
US6635257B1 (en) * 1998-06-24 2003-10-21 Innogentics N.V. Particles of HCV envelope proteins: use for vaccination
US20020160936A1 (en) * 1999-09-29 2002-10-31 Howard J. Worman Hcv e2 protein binding agents for treatment of hepatitis c virus infection
US20040115619A1 (en) * 2000-12-01 2004-06-17 Darren Schofield Monoclonal antibodies specific for the e2 glycoprotein of hepatitic c virus and their use in the diagnosis, treatment , and prevention of hepatitis c
EP1267167A1 (en) * 2001-06-15 2002-12-18 Pfizer Limited Method for identifying HCV entry factors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKIKAWA SHINGO ET AL: "Cell fusion activity of hepatitis C virus envelope proteins", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 11, June 2000 (2000-06-01), pages 5066 - 5074, XP002197964, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2006033012A2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2005012872A3 (en) Liquid crystal based analyte detection
BRPI0516356A (en) yeast therapy for chronic hepatitis c infections
ID26073A (en) METHOD OF DETECTION STATUS OF LIQUID CONSUMPTION, LIQUID CONTAINERS AND VINCES INK
NO20016243D0 (en) Anti-alpha-beta3 recombinant human antibodies, nucleic acids encoding the same, and methods of recycling
WO2001057194A3 (en) Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
WO2005032487A3 (en) Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
WO2006093797A3 (en) Method and kit for detecting porcine reproductive and respiratory syndrome virus
WO2010074575A3 (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
ATE481494T1 (en) TWO-COMPONENT PLANT EXPRESSION SYSTEM DERIVED FROM RNA VIRUSES
WO2007003324A3 (en) Cell-free graft consisting of a matrix and a serum
WO2005087931A8 (en) Modified oncolytic viruses
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
WO2004016586A3 (en) Compositions and methods related to flavivirus envelope protein domain iii antigens
WO2005071414A3 (en) Kit for immobilizing organic substance, organic substance-immobilized structure, and manufacturing methods therefor
WO2006033012A3 (en) Method of screening for modulators of hepatitis c virus infection
WO2004060303A3 (en) Methods and reagents for the enhancement of virus transduction in the bladder epithelium
WO2006038129A3 (en) Hepatitis c virus replication system
WO2005063801A3 (en) Method for decreasing the contact between hepta-repeat region s of the corona-virus spike proteins and use thereof
WO2003059943A3 (en) Conformation-specific, protein kinase binding peptides and related methods and products
WO2002088338A3 (en) Method for replicating the hepatitis c virus
WO2002100900A3 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof
WO2001068818A3 (en) Hcv ns2/3 fragments and uses thereof
WO2006002141A3 (en) Detection of post-translationally modified peptides with liquid crystals
WO2002002631A8 (en) Structure-based drug design method to identify compounds that bind to cd81, a cell receptor for hepatitis-c
WO2004104033A3 (en) Viruses dependent on inducing agents for viral entry into a host cell

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载